LT3458045T - Ebselenas, skirtas naudoti menjero ligos gydymui - Google Patents

Ebselenas, skirtas naudoti menjero ligos gydymui

Info

Publication number
LT3458045T
LT3458045T LTEPPCT/US2017/033379T LTUS2017033379T LT3458045T LT 3458045 T LT3458045 T LT 3458045T LT US2017033379 T LTUS2017033379 T LT US2017033379T LT 3458045 T LT3458045 T LT 3458045T
Authority
LT
Lithuania
Prior art keywords
méniere
ebselen
disease
treatment
Prior art date
Application number
LTEPPCT/US2017/033379T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jonathan Kil
Original Assignee
Sound Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Incorporated filed Critical Sound Pharmaceuticals Incorporated
Publication of LT3458045T publication Critical patent/LT3458045T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/US2017/033379T 2016-05-18 2017-05-18 Ebselenas, skirtas naudoti menjero ligos gydymui LT3458045T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338443P 2016-05-18 2016-05-18
PCT/US2017/033379 WO2017201318A1 (en) 2016-05-18 2017-05-18 Treatment of meniere's disease

Publications (1)

Publication Number Publication Date
LT3458045T true LT3458045T (lt) 2024-12-10

Family

ID=60326098

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/033379T LT3458045T (lt) 2016-05-18 2017-05-18 Ebselenas, skirtas naudoti menjero ligos gydymui

Country Status (19)

Country Link
US (1) US12427138B2 (enExample)
EP (2) EP4461360A3 (enExample)
JP (1) JP7100866B2 (enExample)
KR (1) KR102474830B1 (enExample)
CN (1) CN109475518A (enExample)
AU (1) AU2017267732B2 (enExample)
CA (1) CA3026007A1 (enExample)
DK (1) DK3458045T3 (enExample)
ES (1) ES2990157T3 (enExample)
FI (1) FI3458045T3 (enExample)
HR (1) HRP20241559T1 (enExample)
HU (1) HUE069280T2 (enExample)
LT (1) LT3458045T (enExample)
PL (1) PL3458045T3 (enExample)
PT (1) PT3458045T (enExample)
RS (1) RS66167B1 (enExample)
SI (1) SI3458045T1 (enExample)
SM (1) SMT202400469T1 (enExample)
WO (1) WO2017201318A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021169957A1 (zh) 2020-02-24 2021-09-02 上海科技大学 N-取代吡啶基苯并异硒唑酮化合物的应用
EP4452336A2 (en) * 2021-12-23 2024-10-30 University of Rochester Csf transport pathway for delivery of agents to inner ear
WO2023240094A1 (en) 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Amorphous dosage form containing ebselen
EP4536191A1 (en) * 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Ebselen containing oral dosage forms

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
DE68921436T2 (de) 1988-12-09 1995-08-10 Allergan Inc Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.
DK1471902T3 (da) * 2002-01-04 2014-09-08 Sound Pharmaceuticals Inc Sammensætninger til brug i fremgangsmåder til behandling af høretab
US20070105782A1 (en) * 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
WO2008013866A2 (en) * 2006-07-25 2008-01-31 Hough Ear Institute Methods for treating acute acoustic trauma
EP2310038A4 (en) * 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT
WO2010074992A2 (en) 2008-12-22 2010-07-01 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US9289404B2 (en) * 2011-02-04 2016-03-22 Hough Ear Institute Methods for treating brain injury
CA2842106A1 (en) 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs
CN102526734A (zh) * 2012-01-12 2012-07-04 王玉丰 治疗年龄相关性听力损失的药物组合物及其应用
US20150374779A1 (en) * 2014-06-26 2015-12-31 Auris Medical Ag Pharmacologic treatments of meniére's disease
CA2961380A1 (en) * 2014-09-15 2016-03-24 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
CA3029281A1 (en) * 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US10750005B2 (en) 2018-09-27 2020-08-18 International Business Machines Corporation Selective email narration system

Also Published As

Publication number Publication date
KR102474830B1 (ko) 2022-12-06
EP3458045A1 (en) 2019-03-27
HRP20241559T1 (hr) 2025-02-14
US12427138B2 (en) 2025-09-30
RS66167B1 (sr) 2024-12-31
PT3458045T (pt) 2024-10-28
AU2017267732B2 (en) 2023-04-13
US20200261417A1 (en) 2020-08-20
EP3458045A4 (en) 2020-09-16
DK3458045T3 (da) 2024-11-04
CA3026007A1 (en) 2017-11-23
KR20190043499A (ko) 2019-04-26
ES2990157T3 (es) 2024-11-29
EP3458045B1 (en) 2024-08-21
SI3458045T1 (sl) 2025-03-31
CN109475518A (zh) 2019-03-15
WO2017201318A1 (en) 2017-11-23
JP7100866B2 (ja) 2022-07-14
HUE069280T2 (hu) 2025-02-28
FI3458045T3 (fi) 2024-10-24
PL3458045T3 (pl) 2025-01-07
JP2019516727A (ja) 2019-06-20
EP4461360A2 (en) 2024-11-13
AU2017267732A1 (en) 2018-12-20
EP4461360A3 (en) 2025-01-22
SMT202400469T1 (it) 2025-01-14

Similar Documents

Publication Publication Date Title
IL271046A (en) Compounds for treating huntington's disease
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
PL3672954T3 (pl) Związki, ich sole i ich zastosowanie w leczeniu chorób
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
DK3134386T3 (da) Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
HUE063369T2 (hu) Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben
HUE071155T2 (hu) Biszkolin-tetratiomolibdát Wilson-kór kezelésére
IL263433A (en) Methods for treating alzheimer's disease
DK3463351T3 (da) Behandling til parkinsons sygdom
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
HUE062784T2 (hu) Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
LT3458045T (lt) Ebselenas, skirtas naudoti menjero ligos gydymui
PT3413870T (pt) Igmesina para utilização no tratamento de doença de alzheimer
IL286818A (en) Mirikizumab for use in a method of treating crohns disease
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
PL3148588T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia choroby parkinsona
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
DK3423081T3 (da) Sammensætninger til brug i behandlingen af neurologisk sygdom
HUE048864T2 (hu) Lizobaktin szarvasmarhafélék tõgygyulladásának kezelésében történõ alkalmazásra